A STUDY TO COMPARE THE PHARMACOKINETICS OF PF-06835919 IN PARTICIPANTS WITH AND WITHOUT HEPATIC IMPAIRMENT

Status:
Completed

Trial end date:
2021-07-09

Target enrollment:

Participant gender:

The study is proposed to characterize the effect of varying degrees of hepatic impairment on the plasma PK of PF-06835919

Phase 1

Pfizer